Arvinas Inc
ARVN
Company Profile
Business description
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
Contact
395 Winchester Avenue
5 Science Park
New HavenCT06511
USAT: +1 203 535-1456
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
445
Stocks News & Analysis
stocks
AI stock rout: The US selloff in 4 charts
Worries about Western AI dominance permeated the markets, with Nvidia stock plunging 17% alongside other chipmakers, utilities, and more.
stocks
The ASX share to own forever
An updated outlook on Auckland Airport as we raise our fair value estimate.
stocks
Ask the analyst: Can this big Covid loser scale its former heights?
Corporate Travel Management saw its profits fall through the floor during the pandemic. Our analyst Brian Han answers a reader question on what might be next.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,644.50 | 15.90 | -0.18% |
| CAC 40 | 7,897.37 | 9.21 | -0.12% |
| DAX 40 | 21,430.58 | 148.40 | 0.70% |
| Dow JONES (US) | 44,861.09 | 147.51 | 0.33% |
| FTSE 100 | 8,533.87 | 30.16 | 0.35% |
| HKSE | 20,225.11 | 27.34 | 0.14% |
| NASDAQ | 19,708.84 | 367.00 | 1.90% |
| Nikkei 225 | 39,016.87 | 548.93 | -1.39% |
| NZX 50 Index | 12,957.15 | 42.57 | -0.33% |
| S&P 500 | 6,066.11 | 53.83 | 0.90% |
| S&P/ASX 200 | 8,399.10 | 9.80 | -0.12% |
| SSE Composite Index | 3,250.60 | 2.03 | -0.06% |